Regeneron Pharmaceuticals Inc. recently announced that a Phase 3 study evaluating suptavumab (REGN2222), an antibody to respiratory syncytial virus (RSV), failed to meet its primary endpoint.
The study hoped to show the drug could prevent medically attended RSV infections in infants. According to Regeneron, suptavumab did show signs of efficacy in a subgroup of patients. The company noted suptavumab’s adverse effects were generally on par with the placebo. Regeneron will discontinue additional clinical development options for the antibody.
"We are disappointed in these results, as we had hoped suptavumab might offer a new option for the thousands of infants impacted by serious RSV infections every year," Dr. George Yancopoulos, president and chief scientific officer of Regeneron, said in a statement. "Regeneron has a robust pipeline across many serious diseases, and we look forward to important data readouts from other programs in the coming weeks and months."
Regeneron, a leading biotechnology company, focuses on the invention of medicines that fight serious diseases. The company was founded 30 years ago by physician-scientists and has created six FDA-approved treatments and around a dozen additional product candidates.